IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.06.038
Abstract: Thyroid carcinomas (TCs) bearing BRAF mutations represent approximately 26-53% of human thyroid malignancies and, differently from melanomas, are poorly sensitive to BRAF inhibitors (BRAFi), and develop acquired resistance through activation of alternative signaling pathways. A… read more here.
Keywords: plx4032; braf; stat3 axis; il6 stat3 ... See more keywords
3 Evaluation of HO-1 involvement in melanoma resistance to BRAF inhibitor vemurafenib
Sign Up to like & getrecommendations! Published in 2018 at "Postgraduate Medical Journal"
DOI: 10.1136/postgradmedj-2018-fpm.14
Abstract: Introduction The point mutation of the BRAF gene (BRAFV600E) is present in more than 50% of melanoma. This mutation determinate the continuous activation of MAPK pathway, which favours cell survival and proliferation. Vemurafenib/PLX4032 (PLX4032) is… read more here.
Keywords: melanoma; inhibitor; melanoma resistance; plx4032 ... See more keywords
Cumingianoside A, a Phyto-Triterpenoid Saponin Inhibits Acquired BRAF Inhibitor Resistant Melanoma Growth via Programmed Cell Death
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2019.00030
Abstract: Mutated proto-oncogene BRAF is a bona fide therapeutic target for melanomas. Regrettably, melanoma acquires resistance to BRAF inhibitors, e.g., vemurafenib (PLX4032) casting doubt on this promising melanoma targeted therapy. In this study, we explored the… read more here.
Keywords: melanoma; cuma; plx4032; triterpenoid saponin ... See more keywords
The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms221910767
Abstract: Vemurafenib (PLX4032), small-molecule inhibitor of mutated BRAFV600E protein, has emerged as a potent anti-cancer agent against metastatic melanoma harboring BRAFV600E mutation. Unfortunately, the effect of PLX4032 in the treatment of metastatic BRAF mutated colorectal cancer… read more here.
Keywords: protein; mutant colon; plx4032; colon cancer ... See more keywords